https://www.live-feeds.com/feed/in-autopsy-of-failed-heart-disease-study-astrazeneca-raises-broader-questions-about-silencer-drugsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/in-autopsy-of-failed-heart-disease-study-astrazeneca-raises-broader-questions-about-silencer-drugshttps://www.live-feeds.com/feed/in-autopsy-of-failed-heart-disease-study-astrazeneca-raises-broader-questions-about-silencer-drugs#u52406Sun, 30 Aug 2026 12:55:56 +0000AstraZeneca's eplontersen trial for transthyretin-mediated amyloid cardiomyopathy failed to meet its primary efficacy endpoint. The trial's failure has raised questions about the effectiveness of silencer drugs for heart disease. The failure also impacts Ionis Pharmaceuticals, which co-developed the drug with AstraZeneca. This development has implications for the future of gene silencer treatments.Why it mattersThe failure of AstraZeneca's eplontersen trial has significant implications for the treatment of transthyretin-mediated amyloid cardiomyopathy, a rare and fatal heart dis